Still No Weight Loss at Week 3 on Mounjaro? Here's What's Actually Happening

What the SURMOUNT-1 trial data actually tells us about early weeks

The SURMOUNT-1 trial (published in the New England Journal of Medicine and the foundation for NICE's recommendation of tirzepatide) tracked 2,539 adults over 72 weeks. The headline figures (average body-weight reductions of around 20–21% at the 15mg dose) describe what happened across the whole programme, not what was visible in weeks two or three. Weight loss in these trials was gradual and cumulative: the early weeks were dominated by dose adjustment and GI adaptation, not by the large reductions that came later once participants had been titrated upward and the medicine's full appetite-regulating effect had established itself. That context matters because it means the trial's own data does not support judging week 3 as a useful readout of whether the treatment is working for you. If you want a broader picture of how results build over time, the overview of Mounjaro weight-loss patterns maps this out across the full titration journey.

The NHS's guidance on tirzepatide echoes the same point: treatment response is assessed over months, and the prescriber (not the patient at week three) is the right person to evaluate whether things are on track.

Why the scales at week 3 are a particularly unreliable signal

Several things happen in the first weeks of Mounjaro that affect what the scales say, independently of whether fat is being lost. Tirzepatide slows gastric emptying, which changes the amount of food and fluid sitting in your digestive system at any given moment. If you have also started eating slightly less (which many people do even on the starter dose) your gut contents are simply lighter, but this can be offset on the scales by water retained as your body responds to the new eating pattern. Bowel habits often shift too, which adds further variability. A practical habit worth trying: weigh yourself at the same time on the same day of the week, after using the bathroom and before eating or drinking anything. One consistent weekly reading tells you far more than daily fluctuations that swing by a kilogram or more for reasons unrelated to fat loss. If you're still finding week 3 on Mounjaro shows no weight loss at all, the pages covering what happens at week 2 and what to expect by week 4 give week-by-week context that may be reassuring.

The starter dose: what 2.5mg is actually designed to do

Mounjaro's UK licensed schedule begins at 2.5mg for the first four weeks. This is not a therapeutic target, it is the lowest rung on the titration ladder, chosen specifically because it gives your body time to adapt to the medicine's effects on the gut before the dose increases. Many people feel reduced appetite even at 2.5mg, but the dose is low enough that the signal on body weight is often small or absent in the early weeks. The fuller picture of how long Mounjaro takes to work explains how appetite suppression and weight change typically build through each dose step. The NHS medicines page for tirzepatide describes the dose-escalation process clearly and is worth reading alongside your Patient Information Leaflet. Your prescriber sets the pace of dose changes, that is a clinical decision, not one to make unilaterally based on a slow start in week three. If you have broader questions about how the medicine works, the Mounjaro treatment page covers the mechanism, eligibility and what a clinical assessment involves.

When a lack of progress genuinely does need attention

Three weeks is not the threshold at which prescribers reassess. The clinical benchmark (used by NICE in its guidance on tirzepatide (TA1026)) is whether a patient has achieved less than 5% weight loss after six months at the highest tolerated dose. That is a very different situation from no movement at week 3 on 2.5mg. What is worth noticing early is whether anything is getting in the way of the medicine doing its job: are you eating enough protein to preserve muscle while appetite is suppressed? Are you sleeping reasonably well? Are GI side effects so disruptive that you are not absorbing doses properly? These are questions for your prescriber, not for the scales. If you are concerned about a persistent lack of any progress across the early weeks as a pattern, the broader guide to why weight loss may stall on Mounjaro covers the range of factors clinicians consider, and what week 1 typically looks like gives a useful baseline. For questions about the private prescription route, including what one transparent price covers, the cost context page sets out what is included. When you are ready to speak to a prescriber, starting a free consultation is the right next step.